Belgium· BE-AMP-SAM462551-00
Vimizim 1 mg/ml
A elosulfase alfa product containing elosulfase alfa, registered in Belgium by BioMarin International. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Elosulfase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB12 (elosulfase alfa), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Elosulfase alfa · ATC A16AB12
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Elosulfase Alfa
- Manufacturer
- BioMarin International
- Country
- Belgium (BE)
- ATC code
- A16AB12
- ATC class
- Elosulfase alfa
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb3963378
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elosulfase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayVimizimBioMarin International Limited
- CzechiaVIMIZIMBioMarin International Limited, Dublin
- FinlandVimizimBiomarin International Limited
- IrelandVimizim 1 mg/ml concentrate for solution for infusionBiomarin International Limited
- IcelandVimizimBioMarin International Limited
- PolandVimizimBioMarin International Ltd.
- SwedenVimizim 1 mg/ml Koncentrat till infusionsvätska, lösningBioMarin International Limited
- SwitzerlandVimizim 5mg/5ml, Konzentrat zur Herstellung einer InfusionslösungDRAC AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vimizim
- Liechtenstein · Vimizim
- Norway · Vimizim
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a534e5da-9edc-45bb-a0da-b7e86f01be08 GET /v1/drugs/a534e5da-9edc-45bb-a0da-b7e86f01be08?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Vimizim 1 mg/ml",
"name_fr": "Vimizim 1 mg/ml",
"name_nl": "Vimizim 1 mg/ml",
"amp_code": "SAM462551-00",
"strengths": [
"1.0000"
],
"pack_count": 1,
"substances": [
"Elosulfase Alfa",
"Sorbitol",
"Polysorbate 20",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Elosulfase Alfa",
"authorisation_numbers": [
"EU/1/14/914/001"
]
}See everything about elosulfase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.